Page Tools:

2017 Oncology Nursing Drug Handbook

Author(s): Gail M. Wilkes, MS, APRN-BC, AOCN, Oncology Nursing Consultant, Kilauea, Hawaii
Margaret Barton-Burke, PhD, RN, FAAN, Professor of Oncology Nursing, University of Missouri at St. Louis
  • ISBN-13: 9781284117189
  • ISBN-10:1284117189
  • Paperback    1636 pages      © 2017
Price: $99.95 US List
Add to Cart Request a Review Copy

Written especially for nurses caring for patients with cancer, the 2017 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

Completely revised and updated, the 2017 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.

New drugs include: alectinib (Alecensa), atezolizumab (Tecentriq), cabozantinib tablets (Cabometyx), cabozantinib capsules (Cometriq), cobimetinib tablets (Cotellic), colistin/polymixin B, clotrimazole, daratumumab (Darzalex), elotuzumab (Empliciti), irinotecan liposome injection (Onivyde), ixazomib (Ninlaro), melphalan for injection (Evoela), necitumumab (Portrazza), osimertinib (Targrisso), pentamidine, posaconazole, peramivir, rolapitant (Varubi) , talimogene laherparepvec (Imlygic), Tamiflu, trabectedin (Yondelis),  uridine triacetate (Vistogard granules),  venetoclax (Venclexta), vincristine liposome injection (Marqibo), and zanamivir.

I  Cancer Treatment
1  Introduction to Chemotherapy Drugs
2  Biologic Response Modifier Therapy
3  Cytoprotective Agents
4  Molecularly Targeted Therapies
5  Chemobiotherapy for Noncancer Diseases
II  Symptom Management
6  Pain
7  Nausea and Vomiting
8  Anorexia and Cachexia
9  Anxiety and Depression
III  Complications
10  Managing Tumor-Related Skeletal Events and Hypercalcemia
11  Infection
12  Constipation
13  Diarrhea
Occupational Exposure to Hazardous Drugs
Common Terminology Criteria for Adverse

Gail M. Wilkes, MS, APRN-BC, AOCN-Oncology Nursing Consultant, Kilauea, Hawaii

Gail M Wilkes, MS, APRN-BC, AOCN
Oncology Nursing Consultant
Kilauea, Hawaii
Additional Titles by this Author

Margaret Barton-Burke, PhD, RN, FAAN-Professor of Oncology Nursing, University of Missouri at St. Louis

Additional Titles by this Author